Egon Roesch

This inventor holds 22 USPTO granted patents, primarily in Pharmaceutical Compositions. Top assignee: Boehringer Mannheim Gmbh. Active years: 1976-1989.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Egon Roesch. Retrieved from https://idiyas.com/inventor/egon-roesch

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22

% Patents Active = 100.0

Average Co-Inventor Count = 5.2

ph-index = 8

Forward Citations = 269(Granted Patents)

Location History:

Lampertheim, DE (1976)
Mannheim An Oberen Luisenpark, DE (1976)
Mannheim am Oberen Luisenpark, DE (1976)
Mannheim, DE (1976 - 1989)

Company Filing History:

22 out of 1,164

Boehringer Mannheim Gmbh

patents

Years Active: 1976-1989

Loading Chart...

Areas of Expertise:

Indoline Compounds

Pyrrolobenzimidazoles

Carbazolyl Compounds

Indazoloxypropanolamine Derivatives

Sulphonamidophenylcarboxylic Acid

Quinoxalinyloxy-amino-propanol

Phenoxyalkylcarboxylic Acid

Aminopropanol Compounds

Tricyclic Substituted Aminoalcohols

Therapeutic Compositions

Blood Pressure Lowering

Cardiac Treatment

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4835280 - Indoline compounds for synthesis of pharmaceutically active (1989-05-30),

2. 4695567 - Pyrrolobenzimidazoles, pharmaceutical compositions containing them and (1987-09-22),

3. 4503067 - Carbazolyl-(4)-oxypropanolamine compounds and therapeutic compositions (1985-03-05),

4. 4479962 - Indazoloxypropanolamine derivatives and use in combating, and for the (1984-10-30),

5. 4443477 - Sulphonamidophenylcarboxylic acid compounds and pharmaceutical (1984-04-17),

6. 4438116 - Quinoxalinyloxy-amino-propanol compounds with blood pressure lowering (1984-03-20),

7. 4436742 - 4-Hydroxy-2,1,3-benzthiadiazole compounds and .beta.-adrenergic method (1984-03-13),

8. 4428955 - Benzopyran compounds, pharmaceutical compositions containing them and (1984-01-31),

9. 4367235 - 2-Benzimidazolinone compounds and therapeutic compositions (1983-01-04),

10. 4258058 - Phenoxyalkylcarboxylic acid compounds and thrombocyte-aggregation (1981-03-24),

11. 4232024 - 1-Oxo-1H-pyrimido[6,1-b]benzthiazole derivatives (1980-11-04),

12. 4229464 - Aminopropanol substituted indole compounds and compositions for the (1980-10-21),

13. 4215134 - 4-Hydroxy-2-benzimidazoline-thione compounds and pharmaceutical (1980-07-29),

14. 4153728 - Phenoxyalkylcarboxylic acid compounds and therapeutic compositions (1979-05-08),

15. 4152446 - Aminopropanol compounds and compositions for the treatment of cardiac (1979-05-01),

Title: Innovator Profile: Egon Roesch

Introduction: Egon Roesch is a prominent inventor based in Mannheim, Germany, known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 22 patents, Roesch has made substantial advancements that aim to treat heart and circulatory diseases.

Latest Patents: Roesch's latest innovations include the development of Indoline compounds for the synthesis of pharmaceutically active substances. One of his notable inventions provides Indolines of a specific formula that are particularly effective for treating conditions responding to variations in blood pressure and cardiac output. Additionally, he has worked on pyrrolobenzimidazoles or their tautomers, offering pharmaceutical compositions that hold promise for various therapeutic applications.

Career Highlights: Egon Roesch has been a key figure at Boehringer Mannheim GmbH, where he has channeled his expertise into groundbreaking research. His focus on pharmaceuticals has led to inventions crucial for improving cardiovascular health, showcasing his commitment to innovative medicine.

Collaborations: Throughout his career, Roesch has collaborated with notable colleagues, including Max Thiel and Wolfgang Kampe. These collaborations have undoubtedly contributed to the success of his research initiatives and the advancements in pharmaceutical sciences at Boehringer Mannheim.

Conclusion: Egon Roesch exemplifies the spirit of innovation within the pharmaceutical industry. Through his extensive patent portfolio and collaborations, he continues to make significant strides in developing effective treatments for heart and circulatory diseases, impacting the lives of many. His work is a testament to the importance of research and innovation in addressing critical health challenges.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]